In the next installment of ASTCT’s Titans of Transplant series, Dr. John. F. DiPersio, an internationally recognized leader in hematopoietic stem cell transplantation and acute leukemia and past president of ASTCT (2019) is interviewed by Dr. Roman Shapiro.

About Dr. John F. DiPersio

John F. DiPersio, MD, PhD is deputy director at Alvin J. Siteman Cancer Center, director at Center for Gene and Cellular Immunotherapy and chief of the division of oncology at Washington University School of Medicine in St. Louis and the Virginia E. and Samuel J. Golman professor of medicine. His research focuses on mechanistic and translational aspects of leukemia and stem cell biology. He has played a key role in the clinical development of plerixafor as a mobilizing agent for stem cell transplantation. DiPersio has played a key leadership role in the team-science work at Washington University that has defined the genetic and epigenetic factors that contribute to clonal evolution and relapse in AML. He has served in leadership roles for the American Society of Hematology (ASH), multiple NIH, CIRM, LLS, and CPRIT Study Sections, and has served on NCI’s Board of Scientific Counselors. He is an elected member of ASCI and AAP, and past president of the American Society of Transplantation and Cellular Therapy (2019).

About Dr. Roman Shapiro

Roman Shapiro, MD is a physician working with the bone marrow transplantation group at the Dana-Farber Cancer Institute. His main clinical and academic interest is the prevention and treatment of malignant disease following stem cell transplant. His contributions to science include optimizing the use of natural killer (NK) cell therapy, including cytokine-induced memory-like (CIML) NK cells, for the prevention and treatment of post-transplant relapse of myeloid disease.

The Titans of Transplant series seeks to recognize, celebrate and chronicle the physicians, researchers, pharmacists, nurses, social workers and more who were on the frontlines of the early days of transplant.